Episode 13 - Recognizing and Resolving Clinical Inertia

During this segment, Peter Salgo, MD, defines clinical inertia and explains how it can result in unnecessary, damaging hyperglycemia events that can persist for years in some patients. Additionally, he notes that clinical inertia contributes to costly health complications, higher rates of hospitalizations, and an overall increased use of healthcare resources.

For this reason, Dr Salgo and the panelists explore how healthcare organizations have implemented programs to incentivize healthy behaviors in diabetes patients.

Kari Uusinarkaus, MD, FAAFP, FNLA, discusses how his group has implemented a disease management program that connects an RN “Nurse Navigator” to a patient during hospital discharge. Dr Uusinarkaus explains the importance of this initiative, and highlights another program, called Silver Sneakers, that provides gym access to patients older than 60 years.

However, the panelists recognize that not all initiatives have been successful. For example, despite reducing or limiting the copayments for type 2 diabetes mellitus and obesity drugs, according to Jeffrey D. Dunn, PharmD, MBA, no reliable source of data has revealed changes in patient behavior or improvements in overall outcomes that have come as a result of this reduced cost burden.

Related Videos
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster -
Dr Julie Patterson, National Pharmaceutical Council
Related Content
CH LogoCenter for Biosimilars Logo